Protective effects of Anti-U200 against DMBA-induced tumorigenesis in swiss mice
Main Article Content
Abstract
The incidence and mortality of cancer are increasing worldwide. In addition to conventional therapies, many cancer patients still choose herbal products as adjuvant treatments. However, most of these herbal formulations/products lack evidence-based efficacy. This study investigated the antitumor effect of Anti-U200 hard capsules, a standardized combination of dried extracts of Scutellaria barbata, Hedyotis diffusa, and Ganoderma lucidum, on DMBA-exposed Swiss mice. DMBA was dissolved in olive oil and administered to mice at a total dose of 6 mg for 6 weeks, leading to tumorigenesis. Anti-U200 at the studied doses demonstrated antitumor activities by increasing body weight, lowering mortality, and reducing tumor incidence and yield. Our findings suggest the potential for further research and development of Anti-U200 into an anti-cancer polyherbal preparation that may be a useful adjuvant in cancer prevention and treatment.
Article Details
Keywords
Anti-U200, herbal, tumor, DMBA, mice
References
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249.
3. Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018; 38(1): 325-376.
4. Ma Z, Fan Y, Wu Y, Kebebe D, Zhang B, et al. Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment. Int J Nanomedicine. 2019; 14: 2029-2053.
5. Ma Z, Li N, Zhang B, Hui Y, Zhang Y, et al. Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality. J Nanobiotechnology. 2020; 18(1): 123. doi: 10.1186/s12951-020-00681-8.
6. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015; 93:52-79.
7. Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012; 2(2): 303-336.
8. Zhou X, Seto SW, Chang D, Kiat H, Razmovski-Naumovski V, et al. Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. Front Pharmacol. 2016; 7:201. doi: 10.3389/fphar.2016.00201.
9. Fan Y, Ma Z, Zhao L, Wang W, Gao M, et al. Anti-tumor activities and mechanisms of Traditional Chinese medicines formulas: A review. Biomed Pharmacother. 2020; 132: 110820. doi: 10.1016/j.biopha.2020.110820.
10. Sun K, Wu L, Wang S, Deng W. Antitumor effects of Chinese herbal medicine compounds and their nano-formulations on regulating the immune system microenvironment. Front Oncol. 2022; 12: 949332. doi: 10.3389/fonc.2022.949332.
11. Khan T, Ali M, Khan A, Nisar P, Jan SA, et al. Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects. Biomolecules. 2019; 10(1): 47. doi: 10.3390/biom10010047.
12. Oliveira KD, Avanzo GU, Tedardi MV, et al. Chemical carcinogenesis by DMBA (7,12-dimethylbenzanthracene) in female BALB/c mice: new facts. Brazilian Journal of Veterinary Research and Animal Science. 2015; 52(2): 125-133.
13. Navale AM. Animal Models of Cancer: A Review. IJPSR. 2013; 4(1): 19-28.
14. Liu Y, Yin T, Feng Y, Cona MM, Huang G, et al. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quant Imaging Med Surg. 2015; 5(5): 708-729.
15. Sewduth RN, Georgelou K. Relevance of Carcinogen-Induced Preclinical Cancer Models. Journal of Xenobiotics. 2024; 14(1):96-109.